Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw strong trading volume on Monday . 68,240 shares were traded during mid-day trading, a decline of 6% from the previous session’s volume of 72,456 shares.The stock last traded at $9.71 and had previously closed at $10.32.

Gyre Therapeutics Stock Performance

The stock’s 50 day moving average price is $11.31 and its 200-day moving average price is $12.35.

Insider Buying and Selling

In other news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. The trade was a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 30,054 shares of company stock worth $342,277 in the last three months. 19.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Gyre Therapeutics

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares during the last quarter. Northern Trust Corp raised its stake in Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock valued at $1,251,000 after buying an additional 8,624 shares during the last quarter. Barclays PLC boosted its holdings in Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company’s stock worth $128,000 after acquiring an additional 1,255 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after acquiring an additional 913 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Gyre Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock valued at $1,386,000 after acquiring an additional 918 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.